clinical trial · NCT07867262
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
Genentech, Inc.·phase1·not yet recruiting·n = 165
Advanced or Metastatic Breast CancerGDC-4198FulvestrantLetrozoleGiredestrant
brief summary
The study will evaluate the safety, pharmacokinetics, and preliminary activity of GDC-4198 when given in combination with endocrine therapy (ET) (letrozole, fulvestrant, or giredestrant) as first-line treatment to participants with locally advanced or metastatic Hormone receptor (HR)-positive, Human epidermal growth factor receptor-2 (HER2)-negative breast cancer
started
Dec 15, 2026
primary completion
Aug 15, 2030
completion
Aug 15, 2030
last updated
Nov 5, 2026
official title
A Phase Ib, Multicenter, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Are Sensitive or Resistant to Endocrine Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol